Alliant Energy Corporation vs Twist Bioscience Corp — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: Alliant Energy Corporation is the larger of the two by market cap, and Alliant Energy Corporation pays a 3.27% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and Twist Bioscience Corp for 27 Days on average.
| LNT | TWST | |
|---|---|---|
Market Cap | $16.99B | $10.08B |
Volume | 2,488,387 | 4,229,037 |
Sector | Utilities | Health |
52-Week High | $78.03 | $205.00 |
52-Week Low | $63.21 | $25.45 |
Typical Hold Time | 64 Days | 27 Days |
Enterprise Value | $29.08B | $10.01B |
Dividend Yield | 3.27% | — |
Signals from Pluang's Aura AI — not financial advice
LNT trades at $65.85, up 0.98% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported 2025 revenue of $4.36B and net income of $810M, with a net margin of 18.56%. A $13.4B capital investment plan supports long-term growth, while analyst consensus is a Buy with a $77.00 price target, implying significant upside from current levels.
Outlook remains positive due to steady utility demand and data center growth, but risks include rising debt levels and cost pressures. The stock offers a defensive profile with a 23-year dividend growth history, though valuation multiples like a P/E of 20.74 require sustained earnings expansion to justify further gains.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →